Nature medicine
July 1, 2024
Paul Glue, Colleen Loo, Johnson Fam et al.
60 citations
An extended-release oral tablet form of ketamine (R-107) was effective, safe, and well tolerated for treatment-resistant depression. In a phase 2 trial, 231 adults with severe depression took 120 mg of R-107 daily for 5 days; 168 who responded were then randomly assigned to receive 30, 60, 120, or 180 mg of R-107 or placebo twice weekly for 12 weeks. The 180 mg dose produced a significantly greater reduction in depression scores than placebo, with a mean difference of 6.1 points on the MADRS scale. Relapse rates dropped from 70.6% with placebo to 42.9% with 180 mg. No blood pressure changes occurred, and sedation or dissociation were minimal. Most dosing took place at home.
Nature medicine
July 1, 2024
Paul Glue, Colleen Loo, Johnson Fam et al.
60 citations
An extended-release oral tablet form of ketamine (R-107) was effective, safe, and well tolerated for treatment-resistant depression. In a phase 2 trial, 231 adults with severe depression took 120 mg of R-107 daily for 5 days; 168 who responded were then randomly assigned to receive 30, 60, 120, or 180 mg of R-107 or placebo twice weekly for 12 weeks. The 180 mg dose produced a significantly greater reduction in depression scores than placebo, with a mean difference of 6.1 points on the MADRS scale. Relapse rates dropped from 70.6% with placebo to 42.9% with 180 mg. No blood pressure changes occurred, and sedation or dissociation were minimal. Most dosing took place at home.
Neuropsychiatric disease and treatment
January 1, 2016
Yuan-Yuan Lu, Chieh-Hsin Lin, Hsien-Yuan Lane
17 citations
A 26-year-old man who abused ketamine by inhalation for 12 months developed manic-like symptoms after using the drug. This case suggests a possible relationship between manic symptoms and ketamine abuse, and may be the first report of mania following recreational ketamine use.